Canada, EU To Probe Novartis Diabetes Drug
The European Medicines Agency and Health Canada said they are investigating all diabetes drug brands containing aliskiren after pharmaceutical giant Novartis' Tuesday announcement that it was halting a study involving the drug because of potential dangers.
Aliskiren was approved in 2007 in the EU and U.S. under the brand names Rasilez...
Already a subscriber? Click here to login